132 related articles for article (PubMed ID: 19919087)
1. Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.
Verhoest PR; Proulx-Lafrance C; Corman M; Chenard L; Helal CJ; Hou X; Kleiman R; Liu S; Marr E; Menniti FS; Schmidt CJ; Vanase-Frawley M; Schmidt AW; Williams RD; Nelson FR; Fonseca KR; Liras S
J Med Chem; 2009 Dec; 52(24):7946-9. PubMed ID: 19919087
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo.
Kleiman RJ; Chapin DS; Christoffersen C; Freeman J; Fonseca KR; Geoghegan KF; Grimwood S; Guanowsky V; Hajós M; Harms JF; Helal CJ; Hoffmann WE; Kocan GP; Majchrzak MJ; McGinnis D; McLean S; Menniti FS; Nelson F; Roof R; Schmidt AW; Seymour PA; Stephenson DT; Tingley FD; Vanase-Frawley M; Verhoest PR; Schmidt CJ
J Pharmacol Exp Ther; 2012 May; 341(2):396-409. PubMed ID: 22328573
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase 9: insights from protein structure and role in therapeutics.
Singh N; Patra S
Life Sci; 2014 Jun; 106(1-2):1-11. PubMed ID: 24746902
[TBL] [Abstract][Full Text] [Related]
4. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
5. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.
Bernardelli P; Lorthiois E; Vergne F; Oliveira C; Mafroud AK; Proust E; Pham N; Ducrot P; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Chevalier E; Descours A; Berlioz-Seux F; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4627-31. PubMed ID: 15324877
[TBL] [Abstract][Full Text] [Related]
6. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
[TBL] [Abstract][Full Text] [Related]
7. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
8. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 2: metabolism-directed optimization studies towards orally bioavailable derivatives.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Ducrot P; Wrigglesworth R; Berlioz-Seux F; Coleon F; Chevalier E; Moreau F; Idrissi M; Tertre A; Descours A; Berna P; Li M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4615-21. PubMed ID: 15324875
[TBL] [Abstract][Full Text] [Related]
9. The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.
Deninno MP; Andrews M; Bell AS; Chen Y; Eller-Zarbo C; Eshelby N; Etienne JB; Moore DE; Palmer MJ; Visser MS; Yu LJ; Zavadoski WJ; Michael Gibbs E
Bioorg Med Chem Lett; 2009 May; 19(9):2537-41. PubMed ID: 19339180
[TBL] [Abstract][Full Text] [Related]
10. Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors.
Claffey MM; Helal CJ; Verhoest PR; Kang Z; Fors KS; Jung S; Zhong J; Bundesmann MW; Hou X; Lui S; Kleiman RJ; Vanase-Frawley M; Schmidt AW; Menniti F; Schmidt CJ; Hoffman WE; Hajos M; McDowell L; O'Connor RE; Macdougall-Murphy M; Fonseca KR; Becker SL; Nelson FR; Liras S
J Med Chem; 2012 Nov; 55(21):9055-68. PubMed ID: 23025719
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries.
Birk S; Edvinsson L; Olesen J; Kruuse C
Eur J Pharmacol; 2004 Apr; 489(1-2):93-100. PubMed ID: 15063160
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
[TBL] [Abstract][Full Text] [Related]
13. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity.
Scapin G; Patel SB; Chung C; Varnerin JP; Edmondson SD; Mastracchio A; Parmee ER; Singh SB; Becker JW; Van der Ploeg LH; Tota MR
Biochemistry; 2004 May; 43(20):6091-100. PubMed ID: 15147193
[TBL] [Abstract][Full Text] [Related]
15. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
16. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
Marcoz P; Prigent AF; Lagarde M; Nemoz G
Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
[TBL] [Abstract][Full Text] [Related]
17. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3',5'-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain.
Schwabe U; Miyake M; Ohga Y; Daly JW
Mol Pharmacol; 1976 Nov; 12(6):900-10. PubMed ID: 187926
[No Abstract] [Full Text] [Related]
18. New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.
Devillers I; Pevet I; Jacobelli H; Durand C; Fasquelle V; Puaud J; Gaudillière B; Idrissi M; Moreau F; Wrigglesworth R
Bioorg Med Chem Lett; 2004 Jun; 14(12):3303-6. PubMed ID: 15149695
[No Abstract] [Full Text] [Related]
19. [Phosphodiesterases of cyclic GMP].
Wróblewska H; Gorczyca WA
Postepy Hig Med Dosw; 2001; 55(5):611-27. PubMed ID: 11795198
[TBL] [Abstract][Full Text] [Related]
20. Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.
Lorthiois E; Bernardelli P; Vergne F; Oliveira C; Mafroud AK; Proust E; Heuze L; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Wrigglesworth R; Descours A; Soulard P; Berna P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4623-6. PubMed ID: 15324876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]